<DOC>
	<DOCNO>NCT02794428</DOCNO>
	<brief_summary>A clinical study efficacy oral alpha-difluoromethylornithine ( eflornithine DFMO ) male female subject age 30-60 gastric premalignant lesion two high risk region Latin America .</brief_summary>
	<brief_title>Chemoprevention Gastric Carcinogenesis</brief_title>
	<detailed_description>The primary intervention randomize , double-blind assignment patient daily eflornithine ( 500 mg ) versus placebo 18 month treatment period . Gastric precancerous lesion define chronic atrophic gastritis ( CAG ) intestinal metaplasia ( IM ) . Patients clinically assessed endoscopy gastric biopsy four time point : 0 , 6 , 18 , 24 month . The assessment 0 24 month consider part usual clinical care subject precancerous lesion high risk region . Overall , efficacy eflornithine assess effect : 1 ) DNA damage , 2 ) histology score .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Carcinogenesis</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Patients must history premalignant lesion stomach , atrophic gastritis intestinal metaplasia Patients must pure tone audiometry evaluation document air conduction within 60 day prior registration . Patients must adequate blood count evidence follow result ( obtain within 60 day ) : Blood count : WBC ≥4.0 /mcL , platelets ≥100,000 /mcL hemoglobin ≥11.0 g/dL Kidney function : Creatinine &lt; 1.6 x IULN ( institutional upper limit normal ) Liver function test : Bilirubin ≤2.0 mg/dL AST ( SGOT ) ALT ( SGPT ) ≤2 x IULN Subjects dysplasia ( indeterminate , low grade , high grade ) eligible participation Patients must significant medical psychiatric condition would preclude study completion . Patients hear loss ≥30 dB test frequency ( 250 Hz , 500 Hz , 1,000 Hz , 2,000 Hz , 4,000 Hz , 8,000 Hz ) eligible . Patients must know hypersensitivity eflornithine excipients . Patients must receive corticosteroid , nonsteroidal antiinflammatory drug ( NSAIDs ) , anticoagulant regular intermittent basis . Patients must significant cardiovascular disease history , include uncontrolled blood pressure ( sBP &gt; 150 mmHg ) , myocardial infarction , cerebrovascular accident , heart failure ( New York Heart Association Class III , IV ) . Patients must history gastric esophageal cancer , gastric resection surgery , peptic ulcer disease ( within 6 month ) , H. pylorus treatment ( within 6 month ) , inflammatory bowel disease . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree &gt; 5 year . Patients must receive corticosteroid , nonsteroidal antiinflammatory drug ( NSAIDs ) , anticoagulant regular intermittent basis . Patients must pregnant nursing ( due eflornithine pregnancy class C ) . Women men reproductive potential must agree use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Gastric adenocarcinoma</keyword>
	<keyword>Gastric intestinal metaplasia</keyword>
	<keyword>Atrophic gastritis</keyword>
	<keyword>Gastric premalignant lesion</keyword>
</DOC>